Evaluation of Patients' Preferences for Triamcinolone Acetonide Aqueous, Fluticasone Propionate, and Mometasone Furoate Nasal Sprays in Patients with Allergic Rhinitis

Stokes, Michael; Amorosi, Stacey L.; Thompson, David G.; Dupclay, Leon; Garcia, Jorge; Georges, George

doi:10.1016/j.otohns.2004.04.011

Cited by 33 publications

(31 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study by Bachert et al 54 has been combined with a second study of identical design, and the pooled analysis of these two studies has recently been published. 55 The results of this pooled analysis of 215 patients are essentially the same as those of the Bachert et al study. TANS was associated with significantly less odor and greater liking of odor (p Ͻ 0.001); less taste, less dryness of nose/throat, less aftertaste, and greater overall liking (p Ͻ 0.05 for each attribute) compared with FPNS and MFNS.…”

Section: Choosing An Allergic Rhinitis Therapy For Childrensupporting

confidence: 67%

“…1 Studies show that when adult patients with AR are able to compare products directly, they can distinguish among the sensory attributes of INS sprays, such as odor and taste, and they express definite preferences. [53][54][55][56] In a double-blinded crossover study, 94 patients with AR received single doses, 30 minutes apart, of TANS, FPNS, and BDP nasal spray, in random order. 53 Disregarding BDP, which is not approved for once-daily use, the results showed that patients rated TANS as significantly better than FPNS with respect to odor (p Ͻ 0.001), odor strength (p Ͻ 0.001), and taste (p Ͻ 0.04).…”

Section: Patient Preference and Adherencementioning

confidence: 99%

See 1 more Smart Citation

Allergic Rhinitis in Children: Selecting an Intranasal Corticosteroid

Murphy¹

2005

Pediatric Asthma, Allergy & Immunology

View full text Add to dashboard Cite

Allergic rhinitis affects up to 40% of children in the United States. Proper management of this disease is important for controlling symptoms, improving quality of life, and preventing the development or exacerbation of comorbid diseases such as asthma, sinusitis, otitis media, and respiratory infections. Intranasal corticosteroids (INSs) are recognized as the most effective medication class for controlling allergic rhinitis symptoms and are recommended by guidelines as first-line treatment for moderate to severe cases of allergic rhinitis in patients of all ages. Four once-daily, aqueous formulations of INSs are available in the United States for pediatric patients: budesonide aqueous nasal spray (BANS), fluticasone propionate nasal spray (FPNS), mometasone furoate nasal spray (MFNS), and triamcinolone acetonide aqueous nasal spray (TANS). The results of comparative studies of these INSs show that all four appear to be similar in efficacy and tolerability. The sensory attributes of these INSs do differ and these differences may play a role in the choice of an INS for each patient. Based on studies in adults, patient preference was found to be greater for the sensory attributes of BANS and TANS than for those of FPNS and MFNS, although a number of patients still showed a preference for the attributes of FPNS and MFNS. Similar studies of INS sensory attributes have not been conducted in children. Prescribing the INS with sensory attributes most pleasing to the individual patient may be important in improving patient acceptance of and satisfaction with treatment and perhaps lead to better adherence with therapy. (Pediatr Asthma Allergy Immunol 2005; 18[4]:216-229.)Adapted from Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma.

show abstract

Section: Choosing An Allergic Rhinitis Therapy For Childrensupporting

confidence: 67%

Section: Patient Preference and Adherencementioning

confidence: 99%

Allergic Rhinitis in Children: Selecting an Intranasal Corticosteroid

Murphy¹

2005

Pediatric Asthma, Allergy & Immunology

View full text Add to dashboard Cite

show abstract

“…odor, taste) is a key contributor to patient preference for currently marketed INS products [4]. Unpleasant sensory attributes may be related to decrease patient adherence to treatment.…”

Section: Introduction [1]mentioning

confidence: 99%

Allergic Rhinitis: an Overview

Varshney

2015

Indian J Otolaryngol Head Neck Surg

131

100

View full text Add to dashboard Cite

Allergic rhinitis is an inflammatory disorder of the nasal mucosa induced by allergen exposure triggering IgE-mediated inflammation. Clinically, it is characterized by four major symptoms-rhinorrhea, sneezing, nasal itching, and nasal congestion. It can also be associated with comorbid conditions as Asthma, Atopic Dermatitis & Nasal polyps. Around 20-30 % of the Indian population suffers from allergic rhinitis and that 15 % develop asthma. The diagnosis & treatment of allergic rhinitis should follow ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines while of asthma should follow the GINA (Global Initiative for Asthma) guidelines. The treatment of allergic rhinitis should combine allergen avoidance (whenever possible), pharmacotherapy, and allergen immunotherapy. Intranasal corticosteroids are the most effective modality for treating allergic rhinitis and their sensory attributes are important in patient compliance.

show abstract

“…6 In addition, clinical studies have revealed an inverse relationship between patient preference for and anticipated adherence to an INS therapy and the intensity of certain sensory characteristics of INS sprays. [7][8][9][10] After the implementation of the Montreal Protocol on Substances That Deplete the Ozone Layer banning the use of chlorofluorocarbon propellants, only aqueous-based INS formulation sprays were available. 11,12 Two nasal intranasal steroid aerosol treatments are now available.…”

mentioning

confidence: 99%

A patient preference and satisfaction study of ciclesonide nasal aerosol and mometasone furoate aqueous nasal spray in patients with perennial allergic rhinitis

Berger

Prenner²,

Turner³

et al. 2013

allergy asthma proc

View full text Add to dashboard Cite

Patients' preference and satisfaction with their nasal allergy medications may be influenced by their sensory attributes. This study evaluates patient preference and satisfaction with ciclesonide hydrofluoroalkane nasal aerosol (CIC-HFA) compared with mometasone furoate aqueous nasal spray (MFNS). Symptomatic subjects with perennial allergic rhinitis (PAR) were randomized to CIC-HFA at 74 micrograms or MFNS at 200 micrograms q.d. in an open-label, two-period, crossover study. Subject preference was recorded as total preference score (TPS; average of 17 individual preference items) at the end of treatment period 2, and satisfaction was assessed with a 76-item, self-administered instrument at baseline and at the end of each 2-week treatment period. The primary assessments were TPS and regimen attributes composite satisfaction score composed of two of nine satisfaction subscales: sensory impact (including medication running out of the nose, medication running down the throat, and impact on smell and taste) and regimen management (comprised of issues relating to dosing and ability to remember to take medication). Two hundred ninety-four subjects completed the study. A total of 68.1% of subjects preferred CIC-HFA (p < 0.0001 versus MFNS), with a mean TPS of 68.3 versus 31.7 for the MFNS group. The regimen attributes composite satisfaction score significantly (p < 0.0001 for each treatment period) favored CIC-HFA versus MFNS at the end of treatment period 1 (85.5 vs 77.6) and treatment period 2 (83.0 versus 73.5), respectively. In this study, subjects reported higher preference for and satisfaction with CIC-HFA compared with MFNS, suggesting significant differences in patient perception of attributes in favor of CIC-HFA. Clinical trial registration URL and registration number: www.clinicaltrials.gov/ct2/show/NCT01401465.

show abstract

Evaluation of Patients' Preferences for Triamcinolone Acetonide Aqueous, Fluticasone Propionate, and Mometasone Furoate Nasal Sprays in Patients with Allergic Rhinitis

Abstract: Patients' preferences for the sensory attributes of an intranasal corticosteroid may affect adherence to treatment.

Cited by 33 publications

References 14 publications

Allergic Rhinitis in Children: Selecting an Intranasal Corticosteroid

Allergic Rhinitis in Children: Selecting an Intranasal Corticosteroid

Allergic Rhinitis: an Overview

A patient preference and satisfaction study of ciclesonide nasal aerosol and mometasone furoate aqueous nasal spray in patients with perennial allergic rhinitis

Contact Info

Product

Resources

About